Market News AIOpen the app

AVXL stock news · ANAVEX LIFE SCIENCES CORP.

Stories about ANAVEX LIFE SCIENCES CORP. (AVXL) from the last 90 days, each explained in plain English with whether the news reads good or bad for the company.

Get alerts for AVXL

Follow ANAVEX LIFE SCIENCES CORP. (AVXL) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for AVXL
Free on the App Store and Google Play, or on the web.
  1. Nov 2, 2026, 6:25 PM ET · Market

    Three directors left ANAVEX LIFE SCIENCES CORP., which could change how the company is run.

    Bad for AVXL

    ANAVEX had 3 directors resign, including its board chair, after they cited disagreements over company strategy. The board reset its committees, but the departures raise concerns about oversight.

  2. Oct 20, 2026, 4:23 PM ET · Market

    Anavex Life Sciences Corp. shares news about finishing tests for its drug blarcamesine.

    Neutral

    Anavex finished running 2 studies on how blarcamesine is processed by the body and interacts with other drugs. The filing gives no findings, so it does not change the company’s outlook.

  3. Oct 15, 2026, 5:03 PM ET · Trial

    Anavex Life Sciences Corp. got the green light from the FDA to start a study on its new drug for Fragile X syndrome.

    Good for AVXL

    Anavex can move its planned blarcamesine study for Fragile X syndrome forward after FDA notification. This is a positive step, but it is not treatment approval or proof it works.

  4. Sep 9, 2026, 6:05 PM ET · Trial

    Anavex Life Sciences Corp. says it started a Phase 3 trial for its Rett syndrome drug.

    Good for AVXL

    Anavex said the FDA granted a meeting to discuss pediatric inclusion in its Phase 3 Rett trial. I view this as a positive regulatory step for Anavex.